Form 4: uniQure CEO Exercises and Sells Shares Under 10b5-1 Plan

uniQure's CEO, Matthew C. Kapusta, executed a pre-planned sale of 100,000 ordinary shares after exercising options, as part of a 10b5-1 trading plan.

Summary

• Matthew C. Kapusta, CEO of uniQure N.V., exercised options to purchase 100,000 ordinary shares at a price of $14.71 per share.
• Immediately following the exercise, Mr. Kapusta sold the 100,000 shares at a weighted average price of $15.03 per share.
• The sale was executed as part of a pre-arranged 10b5-1 trading plan adopted on August 12, 2024.
• The trading plan is specifically related to options that are nearing their expiration date, including options expiring on January 1, 2025, and August 25, 2025.
• Following these transactions, Mr. Kapusta directly owns 597,915 ordinary shares.

Sentiment

Score: 6

Explanation: The document reflects a routine transaction under a pre-planned trading strategy. While the sale of shares by the CEO could raise concerns, the use of a 10b5-1 plan mitigates this, resulting in a neutral to slightly positive sentiment.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, which is a legal and transparent way for insiders to trade company stock.
• The CEO's sale of shares at a higher price than the exercise price indicates a potential profit for the CEO.

Negatives

• The sale of 100,000 shares by the CEO could be perceived negatively by some investors, potentially signaling a lack of confidence in the company's future performance, although this is mitigated by the pre-planned nature of the sale.

Risks

• The market may react negatively to the CEO selling a significant number of shares, even if it is part of a pre-planned trading strategy.
• The expiration of the options could lead to further transactions under the 10b5-1 plan, potentially creating volatility in the stock price.

Future Outlook

The document does not provide any specific forward-looking statements beyond the details of the 10b5-1 trading plan and the expiration dates of the options.

Management Comments

• The transactions were executed under a pre-arranged 10b5-1 trading plan adopted on August 12, 2024.

Industry Context

This type of transaction is common for executives of publicly traded companies, especially those with stock options as part of their compensation. The use of a 10b5-1 plan is a standard practice to avoid accusations of insider trading.

Comparison to Industry Standards

• The use of 10b5-1 trading plans is a common practice among executives at publicly traded companies like uniQure, similar to practices at companies such as BioMarin Pharmaceutical and Vertex Pharmaceuticals.
• The exercise and sale of shares by executives is a regular occurrence, and the reported prices are within the typical range for such transactions in the biotech industry.
• The vesting schedule of the stock options, with 25% vesting initially and then quarterly, is a standard approach for equity compensation in the industry.

Stakeholder Impact

• Shareholders may react to the CEO's sale of shares, although the pre-planned nature of the transaction should mitigate any negative impact.
• The transaction has no direct impact on employees, customers, suppliers, or creditors.

Next Steps

• The CEO may continue to execute transactions under the 10b5-1 plan as options approach their expiration dates.
• Investors should monitor future filings for any additional transactions by the CEO or other insiders.

Key Dates

Keywords

uniQure, Matthew Kapusta, CEO, insider trading, 10b5-1 plan, stock options, share sale, equity, QURE